Many Indian engineers seek opportunities abroad early in their careers or after gaining experience, primarily due to the limited exposure to deep tech challenges in India.

Solve Therapeutics has completed a $120 million unlabelled round as it advances a pair of antibody-drug conjugates (ADCs) for cancer that use its proprietary linker technology. San Diego-based Solve ...